RU2016138744A - Антитела, фармацевтические композиции и их применения - Google Patents

Антитела, фармацевтические композиции и их применения Download PDF

Info

Publication number
RU2016138744A
RU2016138744A RU2016138744A RU2016138744A RU2016138744A RU 2016138744 A RU2016138744 A RU 2016138744A RU 2016138744 A RU2016138744 A RU 2016138744A RU 2016138744 A RU2016138744 A RU 2016138744A RU 2016138744 A RU2016138744 A RU 2016138744A
Authority
RU
Russia
Prior art keywords
seq
approximately
amino acid
acid sequence
homologous
Prior art date
Application number
RU2016138744A
Other languages
English (en)
Russian (ru)
Other versions
RU2016138744A3 (show.php
Inventor
Цзянн-Шиюнь ЛАЙ
И-Цзюй ЧЭНЬ
Чэн-Чи ВАН
Йи-Чиень ЦАЙ
Чэн-Дер Тони ЙЮ
Original Assignee
Оби Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оби Фарма Инк. filed Critical Оби Фарма Инк.
Publication of RU2016138744A publication Critical patent/RU2016138744A/ru
Publication of RU2016138744A3 publication Critical patent/RU2016138744A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
RU2016138744A 2014-04-10 2015-04-10 Антитела, фармацевтические композиции и их применения RU2016138744A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461977824P 2014-04-10 2014-04-10
US61/977,824 2014-04-10
US201462057381P 2014-09-30 2014-09-30
US62/057,381 2014-09-30
PCT/US2015/025305 WO2015157629A2 (en) 2014-04-10 2015-04-10 Antibodies, pharmaceutical compositions and uses thereof

Publications (2)

Publication Number Publication Date
RU2016138744A true RU2016138744A (ru) 2018-05-11
RU2016138744A3 RU2016138744A3 (show.php) 2018-05-11

Family

ID=54288553

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016138744A RU2016138744A (ru) 2014-04-10 2015-04-10 Антитела, фармацевтические композиции и их применения

Country Status (17)

Country Link
US (2) US9902779B2 (show.php)
EP (2) EP3129048B1 (show.php)
JP (1) JP2017512759A (show.php)
KR (1) KR101966408B1 (show.php)
CN (2) CN112390887B (show.php)
AU (2) AU2015243246B2 (show.php)
BR (1) BR112016020009A2 (show.php)
CA (2) CA3104268A1 (show.php)
CL (1) CL2016002569A1 (show.php)
ES (1) ES2772817T3 (show.php)
IL (2) IL246837B (show.php)
PH (1) PH12016501976A1 (show.php)
RU (1) RU2016138744A (show.php)
SG (1) SG11201607258SA (show.php)
TW (3) TWI609886B (show.php)
WO (1) WO2015157629A2 (show.php)
ZA (1) ZA201605175B (show.php)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2924286C (en) 2013-09-17 2022-06-21 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
JP2017518958A (ja) 2014-03-19 2017-07-13 マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
EP3129048B1 (en) 2014-04-10 2020-01-15 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof
HK1256912A1 (zh) 2015-09-04 2019-10-04 台湾浩鼎生技股份有限公司 聚糖阵列以及使用方法
CN108472362B (zh) 2015-10-07 2022-03-29 台湾浩鼎生技股份有限公司 新颖糖类抗体、医药组成物及其用途
JP2019513144A (ja) 2016-03-29 2019-05-23 オービーアイ ファーマ，インコーポレイテッド 抗体、医薬組成物及び方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20230110820A (ko) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
KR20190067765A (ko) 2016-07-27 2019-06-17 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
EP3491026A4 (en) 2016-07-29 2020-07-29 OBI Pharma, Inc. HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES
JP2019535731A (ja) * 2016-11-21 2019-12-12 オービーアイ ファーマ，インコーポレイテッド コンジュゲートさせた生物学的分子、医薬組成物及び方法
JP7792191B2 (ja) * 2017-05-24 2025-12-25 ディベロップメント センター フォー バイオテクノロジー グロボｈに対するヒト化抗体および癌治療におけるその使用
US12195554B2 (en) 2018-03-14 2025-01-14 Memorial Sloan Kettering Cancer Center Anti-polysialic acid antibodies and uses thereof
CN112312924A (zh) * 2018-06-01 2021-02-02 台湾浩鼎生技股份有限公司 通过使用抗Globo H或抗SSEA-4抗体与抗负面免疫检查点抗体的联合疗法
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
KR20220016044A (ko) * 2019-03-28 2022-02-08 밍-테인 라이 글로보-h 관련 암 치료법을 위한 동반 진단 검정
WO2022173772A1 (en) * 2021-02-09 2022-08-18 Obi Pharma, Inc. Globo series antigens-binding chimeric antigen receptors and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
AU2001260153B2 (en) 2000-03-24 2006-08-17 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the NKG2D receptor complex
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
DE60124912T2 (de) * 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
EP1505075B1 (en) * 2002-04-30 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Antibody to human insulin-like growth factor
AU2003232456B2 (en) * 2002-05-30 2009-06-04 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
EP2270045B8 (en) 2004-02-06 2015-02-25 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
WO2006003179A2 (en) * 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
CA2572427A1 (en) 2004-07-18 2006-01-18 Heather L. Davis Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
PL1838733T3 (pl) * 2004-12-21 2012-02-29 Medimmune Ltd Przeciwciała skierowane przeciwko angiopoetynie-2 i ich zastosowania
JP5336089B2 (ja) * 2005-02-07 2013-11-06 ロシュ グリクアート アクチェンゲゼルシャフト Ｅｇｆｒを結合する抗原結合分子、それをコードするベクターおよびその使用
WO2006105021A2 (en) * 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
EP1920782A1 (en) 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
CN102065868A (zh) 2008-06-16 2011-05-18 中央研究院 诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途
US8158367B2 (en) 2008-06-16 2012-04-17 Academia Sinica Cancer diagnosis based on levels of antibodies against Globo H and its fragments
TWI392502B (zh) * 2009-06-16 2013-04-11 Academia Sinica 聚己醣抗原及含新穎醣脂質佐劑之相關抗癌疫苗
CN102574915B (zh) * 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
NZ603271A (en) 2010-04-09 2014-05-30 Aveo Pharmaceuticals Inc Anti-erbb3 antibodies
EA201300074A1 (ru) * 2010-07-01 2013-06-28 ДСМ АйПи АССЕТС Б.В. Способ получения представляющего интерес соединения
PE20131340A1 (es) * 2010-08-16 2013-11-29 Amgen Inc Polipeptidos que enlazan miostatina, composiciones y metodos
US20120275996A1 (en) * 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
EP2497782A1 (en) * 2011-03-08 2012-09-12 Alzinova AB Anti oligomer antibodies and uses thereof
CN103959065B (zh) 2011-10-06 2018-07-17 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答
ES2645272T3 (es) 2012-02-24 2017-12-04 Abbvie Stemcentrx Llc Moduladores de DLL3 y procedimientos de utilización
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2017518958A (ja) 2014-03-19 2017-07-13 マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
EP3129048B1 (en) 2014-04-10 2020-01-15 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
CN106456727A (zh) 2017-02-22
TW201546092A (zh) 2015-12-16
EP3129048B1 (en) 2020-01-15
CN106456727B (zh) 2020-11-27
US10815307B2 (en) 2020-10-27
US20180134799A1 (en) 2018-05-17
TW201738276A (zh) 2017-11-01
CN112390887A (zh) 2021-02-23
RU2016138744A3 (show.php) 2018-05-11
IL246837B (en) 2020-08-31
KR20160137984A (ko) 2016-12-02
IL246837A0 (en) 2016-08-31
WO2015157629A2 (en) 2015-10-15
US20170029526A1 (en) 2017-02-02
TWI697503B (zh) 2020-07-01
IL276695A (en) 2020-09-30
BR112016020009A2 (pt) 2017-10-17
CN112390887B (zh) 2023-09-26
CA2941029A1 (en) 2015-10-15
CA2941029C (en) 2021-02-16
EP3662928A1 (en) 2020-06-10
CL2016002569A1 (es) 2017-09-08
AU2018253589B2 (en) 2020-04-16
EP3129048A4 (en) 2017-10-25
KR101966408B1 (ko) 2019-04-05
JP2017512759A (ja) 2017-05-25
PH12016501976A1 (en) 2016-12-19
AU2015243246B2 (en) 2018-09-06
AU2018253589A1 (en) 2018-11-22
SG11201607258SA (en) 2016-10-28
CA3104268A1 (en) 2015-10-15
AU2015243246A1 (en) 2016-09-08
ES2772817T3 (es) 2020-07-08
TWI609886B (zh) 2018-01-01
ZA201605175B (en) 2017-09-27
WO2015157629A3 (en) 2015-12-03
US9902779B2 (en) 2018-02-27
IL276695B (en) 2021-09-30
TWI695013B (zh) 2020-06-01
EP3129048A2 (en) 2017-02-15
TW201738277A (zh) 2017-11-01

Similar Documents

Publication Publication Date Title
RU2016138744A (ru) Антитела, фармацевтические композиции и их применения
RU2018145852A (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
JP2017512759A5 (show.php)
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
JP2020528750A5 (show.php)
HRP20151019T1 (hr) PROTUTIJELA PROTIV c-MET
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
RU2018124859A (ru) Терапевтические антитела к CD47
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
AR103713A1 (es) Anticuerpos contra tau y sus usos
JP2013542194A5 (show.php)
ME02798B (me) Protutijela protiv dkk-1"
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
RU2020127196A (ru) Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
RU2018120695A (ru) Связывающие молекулы, специфичные в отношении asct2, и их применения
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
JP2021500916A5 (show.php)
RU2017137496A (ru) Средство для лечения множественной миеломы (ММ)
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
AR098663A1 (es) Anticuerpos multifuncionales que se unen a egfr y met
RU2019125975A (ru) Связывающие агенты

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180704